Trial Title:
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
NCT ID:
NCT06631391
Condition:
Neuroblastoma
Conditions: Official terms:
Neuroblastoma
Conditions: Keywords:
neuroblastoma, umbilical Cord blood NK cells
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
To evaluate the safety, tolerability and efficacy of umbilical cord blood natural killer
cell injection in the treatment of high-risk, recurrent/refractory neuroblastoma in
children
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
umbilical cord blood NK cells
Description:
This is a phase I prospective clinical trial, including phase Ia and phase Ib. Phase Ia
include 3 dose levels, utilizing a 3+3 design principle, and each dose level will enroll
at least 3 subjects. The recommended dose for phase Ia was used in phase Ib. Each patient
receives two courses of umbilical cord blood NK cell therapy (a total of 8 infusions of
umbilical cord blood NK cells).
Arm group label:
Treatment with umbilical cord blood NK cells
Summary:
Neuroblastoma is the most common extracranial solid tumor, with more than half of the
patients diagnosed at the metastatic stage, classified as high-risk. High-risk
neuroblastoma has a poor prognosis and low survival rate. Despite treatment with
induction, consolidation, and maintenance therapy including GD2 monoclonal antibody, the
survival rate is only about 60%, and many patients still relapse, progress, and die.
NK cell therapy is an emerging immunotherapy that can effectively inhibit and kill tumor
cells without significant adverse reactions, reducing the risk of tumor recurrence and
metastasis, and improving patients' immunity and quality of life. Its safety has been
widely recognized. Currently, clinical trials of NK cell infusion therapy for
neuroblastoma patients are ongoing, and NK cell-based immunotherapy holds great clinical
promise for neuroblastoma. We plan to conduct a phase I clinical trial on umbilical cord
blood NK cell therapy for high-risk, recurrent/refractory neuroblastoma in children to
determine the maximum tolerated dose of umbilical cord blood NK cell therapy in these
patients, thereby laying the foundation for future combination therapies and phase II and
III clinical studies.
Detailed description:
To improve the prognosis of high-risk, Recurrent/Refractory neuroblastoma, we conducted a
prospective Phase I clinical trial. Patients with high-risk and Recurrent/Refractory
neuroblastoma who had undergone multidisciplinary treatment received umbilical cord blood
NK cell infusions. The safety and efficacy of umbilical cord blood NK cells were
evaluated.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
All of the following criteria must be met in order to be eligible for this trial:
1. Agree to participate in the trial and sign a written informed consent form;
2. Age ≤18 years, gender not limited;
3. Karnofsky (≥16 years old) or Lansky (<16 years old) physical status score (Appendix
II) of at least 50;
4. Patients diagnosed with high-risk, recurrent/refractory neuroblastoma in children
according to clinical diagnostic criteria, who have undergone comprehensive
treatment (surgery, chemotherapy, radiotherapy ± stem cell transplantation ± GD2
monoclonal antibody therapy);
5. Expected survival period of at least 12 weeks;
6. The patient must have fully recovered from the acute toxic effects of all previous
anticancer chemotherapy, such as recovery to grade I after bone marrow suppression;
7. Bone marrow suppressive chemotherapy: At least 21 days after the last bone marrow
suppressive chemotherapy (if nitrosoureas were used previously, then 42 days);
8. Investigational drugs or anticancer therapies other than chemotherapy: Must not be
used within 28 days before the planned start of NK cell immunotherapy. Full recovery
from the clinically significant toxicity of that therapy must be confirmed;
9. Hematopoietic growth factors: At least 14 days after the last dose of long-acting
growth factors or 3 days after the last dose of short-acting growth factors;
10. X-ray therapy (XRT): At least 14 days after local palliative XRT (small field port);
if other substantial bone marrow (BM) irradiation is involved, including prior
radioactive iodine metaiodobenzylguanidine (131I-MIBG) treatment, it must end at
least 42 days ago;
11. Stem cell infusion without total body irradiation (TBI): No active graft-versus-host
disease, must have ended at least 56 days after transplantation or stem cell
infusion;
12. Laboratory tests during the screening period must meet the following conditions:
1. Absolute neutrophil count (ANC) ≥1.0×10^9/L (if bone marrow involvement, then
ANC ≥0.5×10^9/L)
2. Platelet count (PLT) ≥75×10^9/L (if bone marrow involvement, then PLT
≥20×10^9/L)
3. Bilirubin ≤1.5 times the upper limit of normal (ULN)
4. Creatinine ≤1.5 times ULN (calculated using the standard Cockcroft-Gault
formula)
5. ALT/AST ≤3 times ULN (if there is liver metastasis, this can be relaxed to 5
times ULN)
13. During the study period, able to comply with outpatient treatment, laboratory
monitoring, and necessary clinical visits; parents/guardians of pediatric or
adolescent participants are capable of understanding, consenting to, and signing the
informed consent form (ICF) and applicable child assent forms before initiating any
protocol-related procedures; with parental/guardian consent, the participant is
capable of expressing their consent (when applicable).
Exclusion Criteria:
Patients who meet any of the following criteria are not eligible for this trial:
1. Symptomatic brain metastases (patients whose brain metastases have been treated and
whose symptoms have been stable for more than two months prior to enrollment may be
enrolled, but must be confirmed by cranial MRI, CT, or venography as having no
symptoms of cerebral hemorrhage);
2. Suffering from the following cardiovascular diseases: grade II or higher myocardial
ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc
interval ≥450 ms for males and ≥470 ms for females); according to the NYHA standard
(Appendix Three), class III-IV heart failure, or echocardiography indicating left
ventricular ejection fraction (LVEF) <50%;
3. Having a history of interstitial lung disease or suffering from interstitial lung
disease at the same time;
4. Coagulation disorders (INR >1.5 or prothrombin time (PT) >ULN +4 seconds or APTT
>1.5 ULN), with a tendency to bleed or currently receiving thrombolytic or
anticoagulant therapy;
5. Arterial/venous thromboembolic events occurring within 12 months before enrollment,
such as cerebrovascular accidents (including transient ischemic attacks, cerebral
hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
6. Known hereditary or acquired bleeding and thrombosis tendencies (such as hemophilia
patients, coagulation disorders, thrombocytopenia, splenomegaly, etc.);
7. Long-term unhealed wounds or fractures (except pathological fractures caused by
tumors);
8. Receiving major surgery or experiencing severe traumatic injuries, fractures, or
ulcers within 4 weeks before enrollment;
9. Factors significantly affecting the absorption of oral medications, such as
inability to swallow, chronic diarrhea, and intestinal obstruction;
10. Experiencing abdominal fistula, gastrointestinal perforation, or abdominal abscess
within 6 months before enrollment;
11. Routine urine tests showing proteinuria ≥ +, and confirmed 24-hour urine protein
quantification ≥1.0 g;
12. Symptomatic serosal effusions requiring symptomatic treatment (including pleural
effusion, ascites, pericardial effusion); Note: Asymptomatic serosal effusions can
be enrolled, symptomatic serosal effusions after active symptomatic treatment
(anticancer drugs cannot be used for treating serosal effusions), judged by the
investigator to meet the enrollment criteria can be enrolled;
13. Active infections requiring antimicrobial treatment (e.g., needing antibacterial
drugs, antiviral drugs, excluding chronic hepatitis B antiviral treatment,
antifungal drug treatment);
14. History of psychoactive substance abuse that cannot be quit or has mental disorders;
15. Participated in other antitumor drug clinical trials within 4 weeks before
enrollment;
16. Receiving systemic hormone therapy or undergoing any form of immunosuppressive
therapy within 2 weeks before the first administration;
17. In the past 2 years, suffered from active autoimmune diseases requiring systemic
treatment (such as using disease-modifying drugs, corticosteroids, or
immunosuppressants); Note: Substitutive treatments (such as thyroxine, insulin, or
physiological corticosteroid replacement therapy for adrenal or pituitary
insufficiency) do not count as systemic treatment;
18. Contraindications for IL-2 use;
19. Suffering from active infections requiring intravenous systemic treatment;
20. Vaccinated with live vaccines within one month before the first use of the study
drug, seasonal influenza vaccination with inactivated virus vaccines is allowed, but
intranasal attenuated live influenza vaccines are not allowed;
21. Previous or concomitant other uncured malignancies, cured skin basal cell carcinoma,
cervical carcinoma in situ, and superficial bladder cancer are excluded;
22. Other conditions judged by the investigator that may affect the conduct of the
clinical study and the determination of study results;
23. Virological tests during the screening period show any of the following:
1. HBsAg positive and HBV DNA exceeds the upper limit of normal
2. Anti-HCV positive and HCV RNA positive
3. HIV positive
24. Undergone allogeneic tissue/organ transplantation;
25. Poor compliance, unable to cooperate with the clinical study.
Gender:
All
Minimum age:
1 Day
Maximum age:
18 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sun Yat-sen University Cancer Center
Address:
City:
Guangzhou
Country:
China
Contact:
Last name:
Yizhuo zhang
Phone:
020-87342460
Email:
zhangyzh@sysucc.org.cn
Start date:
November 1, 2024
Completion date:
November 30, 2029
Lead sponsor:
Agency:
Sun Yat-sen University
Agency class:
Other
Source:
Sun Yat-sen University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06631391
